Additional patent protection for Ygalo granted in Europe until 2032
Stockholm - March 21, 2017 - Oncopeptides AB (Nasdaq Stockholm; ONCO) announced today that the European Patent Office (EPO) recently issued a notice that they intend to grant an additional European patent to Oncoeptides AB.
The patent (EP2701720) covers inter alia the lyophilized formulation of Ygalo that is intended to be launched. The patent can be validated in 38 European countries. The patents will expire in April 2032.
"We are pleased to have received this patent notice. It is in line with expectation but has now also been confirmed. It clearly increases Ygalo’s future commercial value over time, assuming our clinical development programs are successful. It also increases the likelihood of getting a similar patent protection in the United States," said Jakob Lindberg, CEO Oncopeptides.
Oncopeptides is a research and development stage pharmaceutical company developing drugs for treatment of cancer. Since the founding of the Company in 2000, the Company has focused primarily on the development of the product candidate Ygalo, an innovative peptidase-potentiated alkylator intended for effective and focused treatment of blood-based cancer diseases, and in particular multiple myeloma. Ygalo is intended to demonstrate better results from treatment compared to established alternative drugs in the treatment of patients with multiple myeloma. Ygalo could potentially provide treating physicians with a new treatment option for patients suffering from this severe cancer disease. Visit www.oncopeptides.se for more information.
For further information, please contact:
Jakob Lindberg, CEO at Oncopeptides
Rein Piir, Head of Investor Relations at Oncopeptides
This information is such that Oncopeptides is required to publish under the Swedish Financial Instruments Trading Act. The information was released for public disclosure, through the agency of the contact person above, on March 21, 2017 at 08.45 a.m. (CET).